A pre-specified subgroup never overrides the requirements for the full ITT population in a pivotal Phase 2b/3 Alzheimer trial. Regulators approve drugs for the entire enrolled indication, not filtered genetic subsets, unless the trial itself was designed, powered, and randomized exclusively for that subgroup which Anavex did not do.
SIGMAR1 being pre-specified only means the analysis is allowed, not that it can replace the primary-endpoint ITT result. EMA, FDA, PMDA, MHRA all major agencies require the overall study to demonstrate robust efficacy before any subgroup can be used for labeling or refinement. Subgroups cannot “rescue” a weak or borderline overall result. That rule exists to prevent exactly this kind of post-hoc reinterpretation. The OLE is irrelevant for approval: it is unblinded, biased, lacks a concurrent placebo, and cannot serve as confirmatory evidence under EMA law. “New” OLE data also cannot be used during re-examination if it post-dates the CHMP’s initial opinion.
If a company wants approval based on a genetic responder population, they must run a new randomized, prospectively powered, stratified Phase 3 in that exact subgroup. Anavex didn’t. Therefore EMA cannot and will not approve based on ABCLEAR1 or any post-hoc extension of it.
Market Data 
Markets 
